Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

BDX vs DBVT vs BAX vs ALKS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$55.53B
5Y Perf.+3.0%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
BAX
Baxter International Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$9.04B
5Y Perf.-80.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%

BDX vs DBVT vs BAX vs ALKS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BDX logoBDX
DBVT logoDBVT
BAX logoBAX
ALKS logoALKS
IndustryMedical - Instruments & SuppliesBiotechnologyMedical - Instruments & SuppliesBiotechnology
Market Cap$55.53B$1712.35T$9.04B$5.90B
Revenue (TTM)$21.36B$0.00$11.32B$1.56B
Net Income (TTM)$1.14B$-168M$-1.10B$153M
Gross Margin46.5%30.1%65.4%
Operating Margin10.6%-2.7%12.3%
Forward P/E12.3x9.2x24.8x
Total Debt$19.18B$22M$10.00B$70M
Cash & Equiv.$851M$194M$1.97B$1.12B

BDX vs DBVT vs BAX vs ALKSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BDX
DBVT
BAX
ALKS
StockMay 20May 26Return
Becton, Dickinson a… (BDX)100103.0+3.0%
DBV Technologies S.… (DBVT)10041.2-58.8%
Baxter Internationa… (BAX)10019.5-80.5%
Alkermes plc (ALKS)100216.4+116.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: BDX vs DBVT vs BAX vs ALKS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BDX leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Alkermes plc is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. DBVT and BAX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BDX
Becton, Dickinson and Company
The Income Pick

BDX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 0.66, yield 2.7%
  • Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
  • 80.2% 10Y total return vs ALKS's -11.0%
  • Beta 0.66, yield 2.7%, current ratio 1.11x
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +110.4% vs BAX's -41.8%
Best for: momentum
BAX
Baxter International Inc.
The Value Play

BAX is the clearest fit if your priority is value.

  • Better valuation composite
Best for: value
ALKS
Alkermes plc
The Defensive Pick

ALKS is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs BAX's -9.7%
  • 5.4% ROA vs DBVT's -89.0%
Best for: sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthBDX logoBDX8.2% revenue growth vs DBVT's -100.0%
ValueBAX logoBAXBetter valuation composite
Quality / MarginsALKS logoALKS9.8% margin vs BAX's -9.7%
Stability / SafetyBDX logoBDXBeta 0.66 vs BAX's 1.37, lower leverage
DividendsBDX logoBDX2.7% yield, 1-year raise streak, vs BAX's 3.9%, (2 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs BAX's -41.8%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

BDX vs DBVT vs BAX vs ALKS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B
DBVTDBV Technologies S.A.

Segment breakdown not available.

BAXBaxter International Inc.
FY 2025
Medical Products And Therapies
48.8%$5.3B
Healthcare Systems and Technologies
28.3%$3.1B
Pharmaceuticals
22.9%$2.5B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M

BDX vs DBVT vs BAX vs ALKS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGBDX

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

BDX and DBVT operate at a comparable scale, with $21.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to BAX's -9.7%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBDX logoBDXBecton, Dickinson…DBVT logoDBVTDBV Technologies …BAX logoBAXBaxter Internatio…ALKS logoALKSAlkermes plc
RevenueTrailing 12 months$21.4B$0$11.3B$1.6B
EBITDAEarnings before interest/tax$4.2B-$112M$671M$212M
Net IncomeAfter-tax profit$1.1B-$168M-$1.1B$153M
Free Cash FlowCash after capex$3.1B-$151M$501M$392M
Gross MarginGross profit ÷ Revenue+46.5%+30.1%+65.4%
Operating MarginEBIT ÷ Revenue+10.6%-2.7%+12.3%
Net MarginNet income ÷ Revenue+5.3%-9.7%+9.8%
FCF MarginFCF ÷ Revenue+14.7%+4.4%+25.1%
Rev. Growth (YoY)Latest quarter vs prior year-10.6%+2.9%+28.2%
EPS Growth (YoY)Latest quarter vs prior year-2.0%+91.5%-112.0%-4.1%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

BAX leads this category, winning 3 of 6 comparable metrics.

At 24.8x trailing earnings, ALKS trades at a 6% valuation discount to BDX's 26.3x P/E. On an enterprise value basis, BDX's 14.7x EV/EBITDA is more attractive than BAX's 25.4x.

MetricBDX logoBDXBecton, Dickinson…DBVT logoDBVTDBV Technologies …BAX logoBAXBaxter Internatio…ALKS logoALKSAlkermes plc
Market CapShares × price$55.5B$1712.35T$9.0B$5.9B
Enterprise ValueMkt cap + debt − cash$73.9B$1712.35T$17.1B$4.9B
Trailing P/EPrice ÷ TTM EPS26.29x-0.76x-10.01x24.76x
Forward P/EPrice ÷ next-FY EPS est.12.27x9.17x
PEG RatioP/E ÷ EPS growth rate1.59x
EV / EBITDAEnterprise value multiple14.65x25.37x17.25x
Price / SalesMarket cap ÷ Revenue2.54x0.80x4.00x
Price / BookPrice ÷ Book value/share1.73x0.66x1.47x3.28x
Price / FCFMarket cap ÷ FCF20.80x27.99x12.28x
BAX leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to BAX's 1.64x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricBDX logoBDXBecton, Dickinson…DBVT logoDBVTDBV Technologies …BAX logoBAXBaxter Internatio…ALKS logoALKSAlkermes plc
ROE (TTM)Return on equity+4.5%-130.2%-16.5%+8.8%
ROA (TTM)Return on assets+2.1%-89.0%-5.4%+5.4%
ROICReturn on invested capital+4.3%-1.4%+18.9%
ROCEReturn on capital employed+5.4%-145.7%-1.7%+14.2%
Piotroski ScoreFundamental quality 0–97457
Debt / EquityFinancial leverage0.76x0.13x1.64x0.04x
Net DebtTotal debt minus cash$18.3B-$172M$8.0B-$1.0B
Cash & Equiv.Liquid assets$851M$194M$2.0B$1.1B
Total DebtShort + long-term debt$19.2B$22M$10.0B$70M
Interest CoverageEBIT ÷ Interest expense4.09x-189.82x-0.83x32.30x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $2,566 for BAX. Over the past 12 months, DBVT leads with a +110.4% total return vs BAX's -41.8%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs BAX's -24.1% — a key indicator of consistent wealth creation.

MetricBDX logoBDXBecton, Dickinson…DBVT logoDBVTDBV Technologies …BAX logoBAXBaxter Internatio…ALKS logoALKSAlkermes plc
YTD ReturnYear-to-date+0.7%+4.9%-10.2%+25.3%
1-Year ReturnPast 12 months+51.8%+110.4%-41.8%+16.5%
3-Year ReturnCumulative with dividends+5.0%+19.7%-56.3%+14.5%
5-Year ReturnCumulative with dividends+16.9%-69.1%-74.3%+60.9%
10-Year ReturnCumulative with dividends+80.2%-87.0%-42.4%-11.0%
CAGR (3Y)Annualised 3-year return+1.6%+6.2%-24.1%+4.6%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — BDX and ALKS each lead in 1 of 2 comparable metrics.

BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than BAX's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs BAX's 53.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBDX logoBDXBecton, Dickinson…DBVT logoDBVTDBV Technologies …BAX logoBAXBaxter Internatio…ALKS logoALKSAlkermes plc
Beta (5Y)Sensitivity to S&P 5000.66x1.26x1.37x1.06x
52-Week HighHighest price in past year$205.52$26.18$32.68$36.60
52-Week LowLowest price in past year$100.31$7.53$15.73$25.17
% of 52W HighCurrent price vs 52-week peak+74.6%+76.3%+53.6%+96.7%
RSI (14)Momentum oscillator 0–10032.248.144.060.2
Avg Volume (50D)Average daily shares traded2.5M252K8.7M2.3M
Evenly matched — BDX and ALKS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — BDX and BAX each lead in 1 of 2 comparable metrics.

Analyst consensus: BDX as "Buy", DBVT as "Buy", BAX as "Hold", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 12.8% for BDX (target: $173). For income investors, BAX offers the higher dividend yield at 3.87% vs BDX's 2.72%.

MetricBDX logoBDXBecton, Dickinson…DBVT logoDBVTDBV Technologies …BAX logoBAXBaxter Internatio…ALKS logoALKSAlkermes plc
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$172.85$46.33$19.75$44.00
# AnalystsCovering analysts33153628
Dividend YieldAnnual dividend ÷ price+2.7%+3.9%
Dividend StreakConsecutive years of raises1000
Dividend / ShareAnnual DPS$4.17$0.68
Buyback YieldShare repurchases ÷ mkt cap+1.8%0.0%0.0%+0.5%
Evenly matched — BDX and BAX each lead in 1 of 2 comparable metrics.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BAX leads in 1 (Valuation Metrics). 2 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

BDX vs DBVT vs BAX vs ALKS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BDX or DBVT or BAX or ALKS a better buy right now?

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BDX or DBVT or BAX or ALKS?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Becton, Dickinson and Company at 26. 3x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — BDX or DBVT or BAX or ALKS?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: BDX returned +80. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BDX or DBVT or BAX or ALKS?

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 108% more volatile than BDX relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BDX or DBVT or BAX or ALKS?

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Becton, Dickinson and Company grew EPS -0. 5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BDX or DBVT or BAX or ALKS?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -2. 7% for BAX. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BDX or DBVT or BAX or ALKS more undervalued right now?

On forward earnings alone, Baxter International Inc.

(BAX) trades at 9. 2x forward P/E versus 12. 3x for Becton, Dickinson and Company — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — BDX or DBVT or BAX or ALKS?

In this comparison, BAX (3.

9% yield), BDX (2. 7% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is BDX or DBVT or BAX or ALKS better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BDX and DBVT and BAX and ALKS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDX is a mid-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; BAX is a small-cap income-oriented stock; ALKS is a small-cap quality compounder stock. BDX, BAX pay a dividend while DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.0%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

BAX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 18%
  • Dividend Yield > 1.5%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.